12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

131I-TM601: Final Phase II data

Final data from an open-label, dose-escalation U.S. Phase II trial in 69 patients with recurrent malignant glioma showed that 6 intracavitary injections of 131I-TM601 led to a median overall survival of 11.9 months vs. 9.1 months for 3 intracavitary injections...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >